Product Overview
Best Anabolic Steroids lists Semaglutide 10 from Zyvex Pharmaceuticals as a lyophilised powder for weekly subcutaneous use, with semaglutide recorded as the active substance. The molecule is a synthetic analogue of GLP-1, the gut hormone released after a meal, and it was designed by lengthening the peptide and adding a side chain so that it sticks to albumin and survives for days instead of minutes. That single modification is why the same family of drugs works on a weekly schedule.
Two worlds share this molecule and they should not be confused. The approved product exists under the names Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management, with a defined dose ladder, a boxed warning and clinical trials behind it. The vial on this page is the research format of the same active substance: no approved dose, no safety review and no quality assurance by a regulator. The FDA has issued warnings about exactly this category, noting that unapproved versions of GLP-1 drugs have not been assessed for safety, effectiveness or quality, and a buyer who wants the established product should be reading a pharmacy leaflet rather than a research catalogue.
In practice the substance is bought for appetite and body weight. Weight reduction measured in trials is substantial, the appetite effect arrives earlier than the scale movement, and the plan is normally built as a single weekly injection. The training side of such a plan is a separate order: Ligandrol LGD 4033 or Ostarine MK 2866 covers the muscle-retention question while the GLP-1 handles intake.
How It Works
Semaglutide is an agonist at the GLP-1 receptor. It raises insulin release in a glucose-dependent manner, stretches out gastric emptying and lowers the amount a person eats before feeling satisfied. The appetite change is central rather than peripheral: the drug works on the signals that decide how much is enough, which is why users describe smaller portions rather than a deliberate diet.
The pharmacokinetics are unusually long for a peptide. Half-life in the approved form is about one week, and after the last injection the substance can still be measured in blood for several weeks, which means a missed dose matters less than patients expect and an unwanted effect takes time to fade. Neither the prohibited list nor the exemption process applies to GLP-1 agonists, but the incretin class is watched under the monitoring programme, so a routine sample may be screened for it without a finding counting as a violation.
One gap in the record is worth stating. The sources used for this card contain no data on liver toxicity for semaglutide, and no documented effect on water retention, so both would be guesses. The sheet reports them as unconfirmed rather than assigning a rating.
Dosage Protocol
The ladder below belongs to the approved prescription product and is reproduced as a medical reference point. The Zyvex vial has no approved dose of its own, and nobody should read the table as a schedule for a research fill.
| Step | Weekly amount | Step length | Notes |
|---|---|---|---|
| Entry | 0.25 mg subcutaneously | 4 weeks | An adaptation step: the point is tolerance, not weight change |
| Second and third | 0.5 mg, then 1 mg | 4 weeks each | The band in which appetite change and weight loss are usually reported |
| Upper steps | 1.7 mg, then 2.4 mg | 4 weeks each | 2.4 mg weekly is the approved maximum, and it is the dose used in the trial quoted below |
| Female | No separately confirmed dose | - | The approved ladder is not stratified by sex, and the sources give no female-specific figure |
| Administration | Once weekly | - | Subcutaneous injection; the interval is set by the week-long half-life |
The trial that anchors those figures is STEP-1, which enrolled 1961 adults who did not have diabetes and gave them 68 weeks of weekly 2.4 mg injections with a lifestyle programme: average body weight dropped 14.9 percent, while the placebo group lost 2.4 percent. That is a result for the prescription product at its maximum dose, not a prediction for a reconstituted research vial.
Suggested Protocols
Semaglutide is a single weekly injection and is normally run alone. The partners below are catalogue suggestions for the two things a fast deficit threatens: muscle and training quality.
What to Expect
- First weeks. Appetite falls before the scale does. Portions shrink, the sense of fullness arrives earlier, and the entry step is deliberately too low to produce much weight change.
- From 0.5 mg upward. Noticeable weight loss begins here; the headline 14.9 percent figure belongs to the top of the ladder and to 68 weeks of continuous use. Nothing about it transfers to a differently filled research vial.
- Tolerability follows the ladder. Gastrointestinal complaints are dose dependent and cluster around each increase, which is why slow titration matters more than the final number on the syringe.
- Heart rate. A resting rise of about 3 beats per minute is described for the class. Small, consistent, and worth knowing before adding a stimulant to the same plan.
- The limit. About two thirds of the weight lost comes back within a year of stopping, and the average return to the starting weight takes roughly 18 months. The drug manages appetite while it runs; it does not remove the reason the appetite existed.
- Warnings to respect. The approval for this molecule is boxed-warned over C-cell thyroid tumours in rodents and is contraindicated where medullary thyroid cancer appears in a personal or family history, or with MEN-2.
Side Effects and Management
Reconstitution, Storage and Stopping
The reference arithmetic in the sources uses a 5 mg fill with 1 ml of bacteriostatic water, which gives 5 mg per ml; the ratio scales with the nominal fill of the vial, so the concentration is set by the volume added and every dose is read from that figure. Once mixed, the solution is kept at 2 to 8 C and is described as usable for 28 to 30 days. The powder itself stays cold and out of light until the day it is needed.
Buying Semaglutide 10 by Zyvex Pharmaceuticals
This fill appears in the Zyvex Pharmaceuticals catalogue as a lyophilised pack for once-a-week subcutaneous injection, with the approved ladder reprinted on the card as reference material rather than as a schedule for the pack. The other weight-management option on the same shelf is Retatrutide 20, the stimulant route sits next door as Clenbuterol, and the muscle-retention products ordered alongside these vials are Ostarine MK 2866 and Ibutamoren MK 677. Checkout confirms which payment methods and destinations are open to you, every parcel leaves in a plain outer box, and a question about the fill is answered before dispatch.
